Inhibition of miR-802 on insulin secretion by targeting Hnf1B

WANG Danwei; ZHANG Fangfang; JIN Liang; WU Jie

doi:10.11665/j.issn.1000-5048.20200115

Journal of China Pharmaceutical University > 2020 > 51(1): 99-106. > DOI: 10.11665/j.issn.1000-5048.20200115

WANG Danwei, ZHANG Fangfang, JIN Liang, WU Jie. Inhibition of miR-802 on insulin secretion by targeting Hnf1B[J]. Journal of China Pharmaceutical University, 2020, 51(1): 99-106. DOI: 10.11665/j.issn.1000-5048.20200115

Citation:

PDF (4180 KB)

Inhibition of miR-802 on insulin secretion by targeting Hnf1B

More Information

Graphical Abstract

Abstract

Abstract

To investigate the effect of miR-802 on insulin secretion by islet β cells and its mechanism, miR-802 was overexpressed or knocked down in primary islet cells and Min6 cells via transfecting miR-802 mimic and miR-802 inhibitor, respectively. The effect of miR-802 on insulin secretion was detected by ELISA. The target gene of miR-802 was confirmed by miRNA target gene database prediction, luciferase report and Western blot. The function recovery experiment was carried out to clarify the mechanism of miR-802 regulating β cell secretion of insulin. The results showed that overexpression of miR-802 in islet primary cells and Min6 cells inhibited insulin secretion. qPCR and Western blot showed that miR-802 inhibited insulin secretion by inhibiting the transcription and translation of the target gene, hepatocyte nuclear factor 1β(Hnf1B).
- miR-802,
- insulin secretion,
- Hnf1B,
- target gene

FullText(HTML)

References (22)

References

[1]	Shaw JE,Sicree RA,Zimmet PZ.Global estimates of the prevalence of diabetes for 2010 and 2030[J].Diabetes Res Clin Pract,2010,87(1):4-14.
[2]	Du T,Chen J,Shen X.Research advances in susceptibility genes of non-alcoholic fatty liver disease and its association with type 2 diabetes[J].J China Pharm Univ(中国药科大学学报),2018,49(5):537-544.
[3]	Wu Y, Tang TT, Zhu QH, et al. Mechanisms of miR-29a in migration and invasion of breast cancer MCF-7 cells in vitro[J].J China Pharm Univ(中国药科大学学报),2018,49(3):348-353.
[4]	Chen X, Ba Y, Ma LJ, et al. Characterization of microRNAs in serum:a novel class of biomarkers for diagnosis of cancer and other diseases[J].Cell Res,2008,18(10):997-1006.
[5]	van de Bunt M,Gaulton KJ,Parts L,et al.The miRNA profile of human pancreatic islets and beta-cells and relationship to type 2 diabetes pathogenesis[J].PLoS One,2013,8(1):e55272.
[6]	Esguerra JL,Bolmeson C,Cilio CM,et al.Differential glucose-regulation of microRNAs in pancreatic islets of non-obese type 2 diabetes model Goto-Kakizaki rat[J].PLoS One,2011,6(4):e18613.doi: 10.1371/journal.pone.0018613.
[7]	El Ouaamari A,Baroukh N,Martens GA,et al.MiR-375 targets 3′-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells[J].Diabetes,2008,57(10):2708-2717.
[8]	Tang XQ,Muniappan L,Tang GL,et al.Identification of glucose-regulated miRNAs from pancreatic beta cells reveals a role for miR-30d in insulin transcription[J].RNA,2009,15(2):287-293.
[9]	Sun LL,Jiang BG,Li WT,et al.MicroRNA-15a positively regulates insulin synthesis by inhibiting uncoupling protein-2 expression[J].Diabetes Res Clin Pract,2011,91(1):94-100.
[10]	Sun D,Chen J,Wu W,et al.MiR-802 causes nephropathy by suppressing NF-κB-repressing factor in obese mice and human[J].J Cell Mol Med,2019,23(4):2863-2871.
[11]	Kornfeld JW,Baitzel C,Könner AC,et al.Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b[J].Nature,2013,494(7435):111-115.
[12]	Zhang FF,Liu Y,Jin L.Mechanism of lncRNA-Pluto on promoting insulin biosynthesis and secretion[J].J China Pharm Univ(中国药科大学学报),2019,50(4):481-489.
[13]	Wang L,Coffinier C,Thomas MK,et al.Selective deletion of the Hnf1beta(MODY5)gene in beta-cells leads to altered gene expression and defective insulin release[J].Endocrinology,2004,145(8):3941-3949.
[14]	El-Khairi R,Vallier L.The role of hepatocyte nuclear factor 1β in disease and development[J].Diabetes Obes Metab,2016,18(Suppl 1):23-32.
[15]	Su SH,Wu GY,Cheng XD,et al.Oleanolic acid attenuates PCBs-induced adiposity and insulin resistance via HNF1b-mediated regulation of redox and PPAR signaling[J].Free Radic Biol Med,2018,124:122-134.
[16]	Clissold RL,Hamilton AJ,Hattersley AT,et al.HNF1B-associated renal and extra-renal disease-an expanding clinical spectrum[J].Nat Rev Nephrol,2015,11(2):102-112.
[17]	Horikawa Y, Iwasaki N, Hara M, et al. Mutation in hepatocyte nuclear factor-1 beta gene(TCF2)associated with MODY[J].Nat Genet,1997,17(4):384-385.
[18]	Bellanné-Chantelot C,Chauveau D,Gautier JF,et al.Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations[J].Ann Intern Med,2004,140(7):510-517.
[19]	Haldorsen IS,Vesterhus M,Raeder H,et al.Lack of pancreatic body and tail in HNF1B mutation carriers[J].Diabet Med,2008,25(7):782-787.
[20]	Brackenridge A,Pearson ER,Shojaee-Moradie F,et al.Contrasting insulin sensitivity of endogenous glucose production rate in subjects with hepatocyte nuclear factor-1beta and-1alpha mutations[J].Diabetes,2006,55(2):405-411.
[21]	Cebola I,Rodríguez-Seguí SA,Cho CH,et al.TEAD and YAP regulate the enhancer network of human embryonic pancreatic progenitors[J].Nat Cell Biol,2015,17(5):615-626.
[22]	Panneerselvam A,Kannan A,Mariajoseph-Antony LF,et al.PAX proteins and their role in pancreas[J].Diabetes Res Clin Pract,2019,155:107792.

[1]	LU Zhipeng, XU Qinglong, CHEN Panpan, QIN Yajuan, TANG Lijun, LI Tingyou. Research progress of radioprobes targeting fibroblast activating protein[J]. Journal of China Pharmaceutical University, 2022, 53(6): 651-662. DOI: 10.11665/j.issn.1000-5048.20220603
[2]	CHEN Xin, YANG Qian, YOU Qidong, GUO Xiaoke. Advances of inhibitors targeting MLL1-WDR5 protein-protein interaction[J]. Journal of China Pharmaceutical University, 2022, 53(2): 125-136. DOI: 10.11665/j.issn.1000-5048.20220201
[3]	FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
[4]	TANG Keqin, LIN Huaqing, LI Shuhong, DONG Lixin, LU Bohong, JIANG Hong. Advances in tumor targeted nanocrystals[J]. Journal of China Pharmaceutical University, 2020, 51(4): 418-424. DOI: 10.11665/j.issn.1000-5048.20200405
[5]	MEI Jiahao, HONG Ze, WANG Chen. Advances of drugs in targeting cGAS-STING signaling pathway[J]. Journal of China Pharmaceutical University, 2020, 51(3): 249-259. DOI: 10.11665/j.issn.1000-5048.20200301
[6]	JIANG Lu, CHEN Dandan, SUN Minjie, PING Qineng, ZHANG Can. Advances of wax matrix tablets[J]. Journal of China Pharmaceutical University, 2016, 47(4): 497-502. DOI: 10.11665/j.issn.1000-5048.20160418
[7]	YAO Guilin, WANG Haiyong, LU Tao. Advances of the uricosuric drugs[J]. Journal of China Pharmaceutical University, 2016, 47(4): 491-496. DOI: 10.11665/j.issn.1000-5048.20160417
[8]	ZHANG Fangrong, WANG Wei. Advances of synthetic lipoproteins as drug nanovectors[J]. Journal of China Pharmaceutical University, 2016, 47(2): 148-157. DOI: 10.11665/j.issn.1000-5048.20160204
[9]	LIU Fang, SUN Haopeng, YOU Qidong. Advances in small-molecule inhibitors targeting Hsp90-Cdc37 protein-protein interaction[J]. Journal of China Pharmaceutical University, 2015, 46(3): 272-278. DOI: 10.11665/j.issn.1000-5048.20150303
[10]	WANG Yazhe, ZHOU Jianping, DING Yang, WANG Wei. Advances in research of biomimetic drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(3): 267-273. DOI: 10.11665/j.issn.1000-5048.20140303

Cited By

Get Citation

PDF

XML

Article views (322) PDF downloads (709)

Turn off MathJax

Article Contents

Abstract

References

Inhibition of miR-802 on insulin secretion by targeting Hnf1B

Abstract

References

Related Articles

Catalog

Inhibition of miR-802 on insulin secretion by targeting Hnf1B

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content